The first Advanced Therapies Network (ATN) event of the year will be held on 13 February 2019, 6.00 pm at King's College London and will address the importance and the challenges of clinical trials.

Clinical trials are an essential part of developing advanced therapies and accelerating their progression for patient benefit. The event will cover various aspects of how to design and conduct effective clinical trials in this fast-growing area.  Attendees will have the opportunity to listen to experts in the field and debate what makes a clinical trial successful.

Martin O’Kane, Head of Clinical Trials Unit at the Medicines and Healthcare Regulatory Agency (MHRA) and Anna Outhwaite, Head of Advanced Therapy Treatment Centre (ATTC) Network Coordination will talk about the available resources and support for clinical trials in advanced therapies.

Karen Hodgkin, Chief Operating Officer at Cell Medica and John Martin, Professor of Cardiovascular Medicine at University College London will present case studies from their work to illustrate the design, logistics and challenges of advanced therapy trials.

After the presentations there will be a panel discussion, chaired by MedCity Chief Operating Officer Neelam Patel that will explore the subject of advanced therapy clinical trials in a rapidly changing economic and political environment. The event will be followed by a networking session with opportunities to meet and connect with other members.

This event, focussed on clinical trials, will be the first of four held this year which are open to the network’s members. Signing up to become a member of the Advanced Therapies Network is free to those from academia and industry working in advanced therapy. Once signed up you can then register for the event.

Advanced Therapies Network

Led by MedCity in conjunction with King’s College London, Imperial College London, and University College London, the Advanced Therapies Network aims to support knowledge exchange amongst those from academia and industry who are working in cell gene and tissue therapies.

Funded by Research England’s Connecting Capabilities Fund the network will bring together collective expertise through events and the ATN website where members can access exclusive interviews, blogs and information.

Next generation of ‘Collaborate to Innovate’

The event will also launch the next generation of MedCity’s Collaborate to Innovate programme which will focus on advanced therapies.

Also funded by Research England’s Connecting Capabilities Fund, the programme will promote SME engagement in advanced therapies research and build links between industry and higher education sectors. Collaborate to Innovate engages SMEs with innovation or applied research needs and matches them to university research partnerships with complementary skills or expertise through seed funding of up to £150K. 

For more information contact Joana dos Reis  jnevesdosreis@medcityhq.com